Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | GLP1R | P43220 | 8/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25546664 | 1.00 | MEN1 (0.47) | MEN1KMT2ARECQLGLP1RSMN1; SMN2 | |
| SCHEMBL22526369 | 1.00 | MEN1 (0.47) | MEN1KMT2ARECQLGLP1RSMN1; SMN2 | |
| SCHEMBL24470294 | 0.97 | MEN1 (0.45) | MEN1KMT2ARECQLGLP1RSMN1; SMN2 | |
| SCHEMBL26429195 | 0.87 | MEN1 (0.45) | MEN1KMT2ARECQLGLP1R | |
| SCHEMBL24674803 | 0.87 | MEN1 (0.45) | MEN1KMT2AGLP1RSMN1; SMN2 | |
| SCHEMBL25976736 | 0.87 | MEN1 (0.45) | MEN1KMT2ARECQLGLP1RSMN1; SMN2 | |
| SCHEMBL25913029 | 0.87 | MEN1 (0.45) | MEN1KMT2AGLP1RSMN1; SMN2 | |
| SCHEMBL25560484 | 0.87 | MEN1 (0.47) | MEN1KMT2ARECQLGLP1RSMN1; SMN2 | |
| SCHEMBL22790738 | 0.86 | MEN1 (0.52) | MEN1KMT2ARECQL | |
| SCHEMBL22837676 | 0.85 | KMT2A (0.46) | MEN1KMT2AGLP1RSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2021011871-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MEN1 4055/4885KMT2A 445/4885RECQL 2866/4885 |
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MEN1 4055/4885KMT2A 445/4885RECQL 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.